Cumberland Pharmaceuticals Inc (CPIX) is a publicly traded Healthcare sector company. As of May 21, 2026, CPIX trades at $5.47 with a market cap of $76.71M and a P/E ratio of -11.37. CPIX moved +0.00% today. Year to date, CPIX is +38.25%; over the trailing twelve months it is +9.94%. Its 52-week range spans $1.04 to $7.25. Rallies surfaces CPIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in CPIX news today?
Cumberland Pharmaceuticals Reports Q1 $3.3M Loss and $100M Apotex Brand Sale: Cumberland Pharmaceuticals reported a Q1 net loss of $3.3 million on $9.1 million revenue and an adjusted loss of $0.13 per share. It agreed to sell its FDA-approved brands to Apotex for $100 million cash while retaining its ifetroban development pipeline, which holds Fast Track designation for Duchenne muscular dystrophy.
CPIX analyst coverage data. Average price target: $0.00.
Common questions about CPIX
What changed in CPIX news today?
Cumberland Pharmaceuticals Reports Q1 $3.3M Loss and $100M Apotex Brand Sale: Cumberland Pharmaceuticals reported a Q1 net loss of $3.3 million on $9.1 million revenue and an adjusted loss of $0.13 per share. It agreed to sell its FDA-approved brands to Apotex for $100 million cash while retaining its ifetroban development pipeline, which holds Fast Track designation for Duchenne muscular dystrophy.
Does Rallies summarize CPIX news?
Yes. Rallies summarizes CPIX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is CPIX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CPIX. It does not provide personalized investment advice.
